Abbott, a maker of products for diagnostics, medical devices, nutrition and pharmaceuticals, is collaborating with two pharmaceutical companies, Celgene and Agios, in an effort to develop a system for diagnostic testing that identifies genomic mutations associated with acute myeloid leukemia (AML). According to Agios, about 20 percent of patients who have developed AML share a common mutation of the isocitrate dehydrogenase (IDH) enzymes. The IDH enzymes break down nutrients and supply energy to cells as they mature and develop. A recent study published by Leukemia, an online journal for science and medical information, shows that specific medications created to target IDH mutations have potential. The researchers advised that analysis ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.